Skip to main content
Clinical Trials/ACTRN12615001265561
ACTRN12615001265561
Recruiting
Phase 1

In patients with Non-Small Cell Lung Cancer (NSCLC) is Pentixafor-PET a more accurate imaging test than FDG-PET for local staging and identifying sites of metastatic disease?

Oceanic Molecular Imaging0 sites30 target enrollmentNovember 19, 2015

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
on-small cell lung cancer
Sponsor
Oceanic Molecular Imaging
Enrollment
30
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 19, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Oceanic Molecular Imaging

Eligibility Criteria

Inclusion Criteria

  • a.Histological diagnosis of NSCLC.
  • b.Requires 18F\-FDG PET/CT as part of routine work\-up for diagnosis and staging.
  • c.Competent to provide informed consent
  • d.Not pregnant or breastfeeding

Exclusion Criteria

  • Pregnant or breastfeeding
  • Lack of indication or contraindication to FDG PET

Outcomes

Primary Outcomes

Not specified

Similar Trials